In vivo age dependency of unfractionated heparin in infants and children

Thrombosis Research

Volumn 123, Issue 5, 2009, Pages 710-714

  Newall, Fiona ^a,b,c   Ignjatovic, Vera ^a,b,c   Summerhayes, Robyn ^a,c   Gan, Andrew ^b   Butt, Warwick ^d   Johnston, Linda ^a,b,c   Monagle, Paul ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Royal Children's Hospital

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d Royal Children's Hospital

Author keywords

Anti Xa; APTT; Children; ETP; Unfractionated Heparin

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; HEPARIN; PROTHROMBIN A; THROMBIN;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; INFANT; INTENSIVE CARE UNIT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ADOLESCENT; AGE FACTORS; ANTICOAGULANTS; ANTITHROMBIN III; ANTITHROMBINS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPARIN; HUMANS; INFANT; MALE; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; PROTHROMBIN; THROMBIN;

EID: 60449105478     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.07.009     Document Type: Article

References (19)

1. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin. Chest 126 (2004) 188S-203S
2. Monagle P., Chan A., Massicotte P., Chalmers E., and Michelson A. Antithrombotic therapy in children. Chest 126 (2004) 645S-687S
3. Ignjatovic V., Summerhayes R., Than J., Gan A., and Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost 4 (2006) 2280-2282
4. Ignjatovic V., Furmedge J., Newall F., Chan A., Berry L., Fong C., et al. Age-related differences in heparin response. Thromb Res 118 (2006) 741-745
5. Kitchen S., Theaker J., and Preston F. Monitoring Unfractionated Heparin Therapy: Relationship Between Eight Anti-Xa Assays and a Protramine Titration Assay. Blood Coagul Fibrinolysis 11 (2000) 137-144
6. Ignjatovic V., Summerhayes R., Gan A., Than J., Chan A., Cochrane A., et al. Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate?. Thromb Res 120 (2007) 347-351
7. Berry L., Andrew M., Post M., Ofosu F., and O'Brodovich H. A549 lung epithelial cell line synthesize anticoagulant molecules on the cell surface, matrix and in conditioned media. Am J Resir Cell Mol Biol 4 (1991) 338-346
8. Monagle P., Barnes C., Ignjatovic V., Furmedge J., Newall F., Chan A., et al. Developmental haemostasis: Impact for clinical haemostasis laboratories. Thromb Haemost 95 (2006) 362-372
9. Schmidt B., Buchanan M., Ofosu F., Brooker L., Hirsh J., and Andrew M. Antithrombotic properties of heparin in a neonatal piglet model of thormbin-induced thrombosis. Thromb Haemost 60 (1988) 289-292
10. Schmidt B., Mitchell L., Ofosu F., and Andrew M. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 112 (1988) 641-643
11. Schmidt B., Ofosu F., Mitchell L., Brooker L., and Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 25 (1989) 405-408
12. Andrew M., Ofosu F., Schmidt B., Brooker L., Hirsh J., and Buchanan M. Heparin Clearnace and Ex Vivo Recovery in Newborn Piglets and Adult Pigs. Thromb Res 52 (1988) 517-527
13. Kuhle S., Eulmesekian P., Kavanagh B., Massicotte P., Vegh P., and Mitchell L. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica 92 (2007) 244-247
14. Kuhle S., Eulmesekian P., Kavanagh B., Massicotte P., Vegh P., Lau A., et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 92 (2007) 554-557
15. Keckler S., St.Peter S., Valusek P., Tsao K., Snyder C., Holcomb G., et al. VACTERL anomalies in patients with esophageal atresia: an updated delineation of the specturm and review of the literature. Pediatr Surg Int 23 (2007) 309-313
16. Despotis G., Summerfield A., Joist J., Goodnough L., Santoro S., Spitznagel E., et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108 (1994) 1076-1082
17. Brill-Edwards P., Ginsberg J., Johnston M., and Hirsh J. Establishing a Therapeutic Range for Heparin Therapy. Ann Intern Med 119 (1993) 104-109
18. Baker B., Adelman A., Smith P., and Osborn J. Inability of the activated partial thromboplasti time to predict heparin levels: time to reassess guidelines for heparin assays. Arch Intern Med 157 (1997) 2475-2479
19. Ignjatovic V., Greenway A., Summerhayes R., and Monagle P. Thrombin generation: the functional role of alpha-2-macroglobulin and influence of Developmental Haemostasis. Br J Haematol 138 (2007) 366